Naperville, IL -- (SBWIRE) -- 10/21/2014 -- Reportstack, provider of premium market research reports announces the addition of EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023 market report to its offering
EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023
Summary:
Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease, and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial.
The publisher epidemiologists forecast that the total prevalent cases of dyslipidemia in the 8MM will increase from 572,418,492 total prevalent cases in 2013, to 685,905,635 total prevalent cases in 2023, at an Annual Growth Rate (AGR) of 1.99%. All markets will see an increase in the total prevalent cases of dyslipidemia at varying AGRs, except for Germany, which will see a decrease. The 8MM had an estimated 3,339,447 total prevalent cases of FH in 2013, and the number of total prevalent cases of FH is expected to increase to 4,365,831 by 2023, at an AGR of 3.07%. All markets will see an increase in the total prevalent cases of FH at varying AGRs, except for Japan, which will see a decrease. Additionally, The publisher epidemiologists forecast that the total prevalent cases of increased LDLc in the 8MM will increase from 345,008,543 total prevalent cases in 2013 to 411,737,455 total prevalent cases in 2023, at an AGR of 1.93%. All markets will see an increase in the total prevalent cases of increased LDLc at varying AGRs, except for Germany, which will see a decrease. The 8MM had an estimated 10,777,756 total prevalent cases of very high TG (=500mg/dL) in 2013, and the number of total prevalent cases of very high TG is expected to increase to 12,746,492 by 2023, at an AGR of 1.83%. All markets will see an increase in the total prevalent cases of very high TG at varying AGRs, except for Germany and Japan, which will see a decrease.
The publisher epidemiologists used comprehensive, country-specific data from population based national health surveys such as NHANES in the US, the HSE in the UK, and the CHNS in urban China, in addition to data from peer-reviewed journal articles, to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of dyslipidemia, and other therapeutically significant patient populations including the total prevalent cases of increased LDLc and very high TG (=500mg/dL). For all the 8MM, the total prevalent cases of dyslipidemia, increased LDLc, and very high TG (=500mg/dL) were segmented by age and sex, which facilitates an understanding of the distribution of disease within the population, and informs strategies to improve the management of disease.
Scope:
- The Dyslipidemia EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for dyslipidemia in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast for the total prevalent cases of dyslipidemia (defined as: increased low-density lipoprotein cholesterol [LDLc], high triglycerides [TG] [=200mg/dL], or low levels of high-density lipoprotein cholesterol [HDLc]), as well as the total prevalent cases of increased LDLc (=115mg/dL to =160mg/dL based on country-specific cut-offs), and very high TG (=500mg/dL), segmented by sex and age (in 10-year intervals beginning at 20 years and ending at =70 years). Additionally, the forecast provides the total prevalent cases of familial hypercholesterolemia (FH) in these markets.
- The dyslipidemia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to buy:
- Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market.
- Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for dyslipidemia therapeutics in each of the markets covered.
Complete report is available
http://www.reportstack.com/product/178909/epicast-report-dyslipidemia-epidemiology-forecast-to-2023.html
Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604